You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-H

Showing 1 - 25 of 2,526
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • (no location specified)
Apr 23, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

    Not yet recruiting
    • MSI-H/dMMR Gastroesophageal-junction Cancer
    • MSI-H/dMMR Gastric Cancer
    • (no location specified)
    Oct 30, 2023

    Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (PD-1 inhibitor)

    Recruiting
    • Gastric or Gastroesophageal Junction Adenocarcinoma
    • PD-1 inhibitor
    • Guangzhou, China
      Sun Yat-sen University Cancer Center
    Aug 9, 2023

    Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

    Not yet recruiting
    • Adenocarcinoma - GEJ
    • Gastric Adenocarcinoma
    • (no location specified)
    Sep 26, 2023

    Neoadjuvant Envafolimab in Resectable and Locally Advanced

    Not yet recruiting
    • Locally Advanced Rectal Carcinoma
    • MSI-High
    • (no location specified)
    Dec 9, 2022

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

    Recruiting
    • dMMR Colorectal Cancer
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Apr 13, 2023

    Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

    Not yet recruiting
    • Colonic Neoplasms
    • Dostarlimab
    • +2 more
    • (no location specified)
    May 3, 2023

    DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

    Not yet recruiting
    • Endometrial Cancer
    • (no location specified)
    Feb 14, 2023

    MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

    Not yet recruiting
    • MSI-H
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 26, 2023

    MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

    Terminated
    • MSI-H/dMMR Solid Tumor
    • Guangzhou, Guangdong, China
      Sun Yat-Sen University Cancer Center
    Oct 17, 2022

    Tumors, Rectal Trial (Dostarlimab)

    Not yet recruiting
    • Neoplasms, Rectal
    • Dostarlimab
    • (no location specified)
    Feb 2, 2023

    MSI-H, PD-1 Immunotherapy, Gastric Cancer Trial in Shanghai (SOX, XELOX, Observation)

    Not yet recruiting
    • MSI-H
    • +3 more
    • Shanghai, China
      Dazhi Xu
    Jul 20, 2022

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    Immunotherapy in MSI-H Metastatic Colorectal Cancer

    Recruiting
    • Colorectal Cancer
    • Carpi, Modena, Italy
      Ospedale Ramazzini
    Sep 5, 2022

    Rectal Tumors Trial in Cleveland (Pembrolizumab, External beam radiation, Capecitabine)

    Recruiting
    • Rectal Neoplasms
    • Cleveland, Ohio
      Cleveland Clinic, Case Comprehensive Cancer Center
    Jan 25, 2023

    Registry Study in MSI/dMMR Solid Tumors

    Not yet recruiting
    • DMMR Cancer
    • +2 more
      • (no location specified)
      Aug 21, 2023

      Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

      Not yet recruiting
      • Colorectal Cancer Stage IV
      • +2 more
      • (no location specified)
      Jun 19, 2022

      Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

      Recruiting
      • Colorectal Cancer
      • +3 more
      • Neoadjuvant therapy with PD-L1 inhibitor
      • Guangzhou, Guangdong, China
        the Third Affiliated Hospital of Sun Yat-Sen University
      May 10, 2022

      Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

      Terminated
      Has Results
      • Locally Advanced Malignant Solid Neoplasm
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Dec 22, 2022

      Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

      Active, not recruiting
      Has Results
      • Colorectal Carcinoma
      • (no location specified)
      Oct 28, 2022